| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 70,022 | 80,983 | ||
| Marketable securities | 223,730 | 244,567 | ||
| Accounts receivable, net | 50,541 | 44,993 | ||
| Inventory | 2,042 | 2,169 | ||
| Prepaid expenses and other current assets | 21,161 | 22,209 | ||
| Total current assets | 367,496 | 394,921 | ||
| Property and equipment, net | 2,460 | 2,420 | ||
| Operating lease right-of-use assets | 4,368 | 4,804 | ||
| Finance lease right-of-use assets | 5,071 | 5,244 | ||
| 2025 | 366 | - | ||
| 2026 | 1,463 | - | ||
| 2027 | 1,463 | - | ||
| 2028 | 1,463 | - | ||
| 2029 | 1,463 | - | ||
| Thereafter | 8,285 | - | ||
| Hetlioz | 14,503 | - | ||
| 2025 | 1,386 | - | ||
| 2026 | 5,544 | - | ||
| 2027 | 5,544 | - | ||
| 2028 | 5,544 | - | ||
| 2029 | 5,544 | - | ||
| Thereafter | 70,776 | - | ||
| PONVORY | 94,338 | - | ||
| Intangible assets, net | 108,841 | 110,593 | ||
| Deferred tax assets | 103,073 | 97,143 | ||
| Non-current inventory and other | 9,831 | 9,621 | ||
| Total assets | 601,140 | 624,746 | ||
| Accounts payable and accrued liabilities | 47,619 | 57,119 | ||
| Product revenue allowances | 70,251 | 64,370 | ||
| Total current liabilities | 117,870 | 121,489 | ||
| Operating lease non-current liabilities | 3,419 | 3,877 | ||
| Finance lease non-current liabilities | 2,808 | 3,083 | ||
| Other non-current liabilities | 11,044 | 9,968 | ||
| Total liabilities | 135,141 | 138,417 | ||
| Common stock, 0.001 par value 150,000,000 shares authorized 59,095,630 and 58,310,644 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 59 | 59 | ||
| Additional paid-in capital | 718,979 | 716,867 | ||
| Accumulated other comprehensive income | 540 | 396 | ||
| Accumulated deficit | -253,579 | -230,993 | ||
| Total stockholders equity | 465,999 | 486,329 | ||
| Total liabilities and stockholders equity | 601,140 | 624,746 | ||
Vanda Pharmaceuticals Inc. (VNDA)
Vanda Pharmaceuticals Inc. (VNDA)